Table 1.
Comparisons of clinical characteristics and oral medications between the low and high apo-C3 groups.
| Low apo-C3 group (≤ 8.5 mg/dL, n = 52) | High apo-C3 group (> 8.5 mg/dL, n = 46) | P-value | |
|---|---|---|---|
| Age (years) | 67.9 ± 1.2 | 71.5 ± 1.4 | 0.0533 |
| Male patients, no. (%) | 40 (76.9) | 34 (73.9) | 0.7295 |
| BMI | 23.8 ± 0.5 | 25.7 ± 0.5 | 0.001* |
| Clinical history | |||
| DM | 15 (28.8) | 17 (37.0) | 0.3929 |
| Hypertension | 34 (65.4) | 38 (82.6) | 0.0539 |
| Family history | 6 (11.5) | 9 (19.6) | 0.2707 |
| Smoking | 15 (28.8) | 17 (37.0) | 0.3929 |
| Previous PCI | 23 (44.2) | 15 (32.6) | 0.2386 |
| Previous MI | 9 (17.3) | 7 (15.2) | 0.7799 |
| Oral medications | |||
| CCB | 24 (46.2) | 25 (54.3) | 0.4181 |
| ACEI/ARB | 25 (48.1) | 21 (45.7) | 0.8103 |
| Antiplatelet drugs | 38 (73.1) | 31 (67.4) | 0.5383 |
| Anti-DM drugs | 9 (17.3) | 6 (13.0) | 0.5585 |
| Fibrates | 1 (1.9) | 1 (2.2) | 0.9302 |
| Statin | 22 (42.3) | 23 (50.0) | 0.4457 |
Values are presented as mean ± standard errors or as numbers (percentages) of patients.
*P < 0.05.
apo-C3 apolipoprotein C3; BMI body mass index; DM diabetes mellitus; PCI percutaneous coronary intervention; MI myocardial infarction; CCB calcium-channel blocker; ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker.